← All trials
NCT05611372
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2023
- Primary completion
- Dec 31, 2025
- Completion date
- Dec 31, 2026
- First posted
- Nov 10, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 732
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Zhejiang UniversityLead sponsor
- Capital Medical UniversityCollaborator
- Fujian Medical UniversityCollaborator
- Guizhou Medical UniversityCollaborator
- Fudan UniversityCollaborator
- Nanjing UniversityCollaborator
- Shandong UniversityCollaborator
- Soochow UniversityCollaborator
- Zhejiang UniversityCollaborator
- Hangzhou Normal UniversityCollaborator
- Anhui Medical UniversityCollaborator
- Dalian Medical UniversityCollaborator
- Guangzhou Medical UniversityCollaborator
- Sichuan UniversityCollaborator
- Jiao Tong UniversityCollaborator
- Zhejiang UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.